Calles-Monar Paola S, Sanabria María R, Alonso-Tarancon Ana M, Coco-Martin Rosa M, Mayo-Iscar Agustín
Ophthalmology Department, San Telmo Hospital, Palencia University Hospital Complex, 34004, Palencia, Spain.
Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain.
Drugs Aging. 2022 May;39(5):355-366. doi: 10.1007/s40266-022-00937-y. Epub 2022 Apr 29.
The success of intravitreal treatment for neovascular age-related macular degeneration (nAMD) depends on maximal adherence to treatment, which in turn requires patient satisfaction.
The aim of this study was to assess the factors associated with nAMD patient satisfaction to implement actions to improve treatment experiences and increase adherence.
This was a prospective, observational, analytical, cross-sectional study.
Our study included 100 consecutive nAMD patients under intravitreal treatment for at least 1 year.
Patients completed the Macular Disease Treatment Satisfaction Questionnaire (MacTSQ) and the EuroQol Visual Analog Scale (EQ VAS). A logistic regression was estimated to model the low values of the satisfaction score (MacTSQ < 50).
The mean age of patients was 82.1 ± 7.8 years and 62% were female. Males (p = 0.002) and patients who improved their visual acuity (p = 0.004) were more satisfied, while patients who received a higher number of injections (p = 0.036) and treatment in both eyes (p = 0.001) were less satisfied. Higher health-related quality of life was related to higher satisfaction. The sensitivity and specificity of the predictive model were 75.8% and 76.1%, respectively. Factors independently associated with low satisfaction were female sex (odds ratio [OR] 6.84), going to the clinic alone (OR 8.51), longer duration of treatment (OR 0.62), receiving treatment in both eyes (OR 3.54), and suffering a decline in visual acuity (OR 3.30). The questionnaire revealed patients' needs for more information and injection points closer to their homes.
Well-defined areas for improvement were identified, i.e. to improve the information offered to each patient, to incorporate new long-acting drugs, and to establish locations for injection services in peripheral areas.
玻璃体内注射治疗新生血管性年龄相关性黄斑变性（nAMD）的成功取决于最大程度地坚持治疗，而这又需要患者的满意度。
本研究的目的是评估与nAMD患者满意度相关的因素，以便采取行动改善治疗体验并提高依从性。
这是一项前瞻性、观察性、分析性横断面研究。
我们的研究纳入了100例接受玻璃体内注射治疗至少1年的连续nAMD患者。
患者完成黄斑疾病治疗满意度问卷（MacTSQ）和欧洲五维健康量表视觉模拟量表（EQ VAS）。采用逻辑回归对满意度得分低（MacTSQ < 50）的情况进行建模。
患者的平均年龄为82.1 ± 7.8岁，62%为女性。男性（p = 0.002）和视力改善的患者（p = 0.004）更满意，而接受注射次数较多的患者（p = 0.036）和双眼接受治疗的患者（p = 0.001）满意度较低。更高的健康相关生活质量与更高的满意度相关。预测模型的敏感性和特异性分别为75.8%和76.1%。与低满意度独立相关的因素包括女性（优势比[OR] 6.84）、独自前往诊所（OR 8.51）、治疗时间较长（OR 0.62）、双眼接受治疗（OR 3.54）以及视力下降（OR 3.30）。问卷显示患者需要更多信息以及离家更近的注射点。
确定了明确的改进领域，即改善向每位患者提供的信息、纳入新的长效药物以及在周边地区设立注射服务地点。
